The government said it is difficult due to concerns over weakening NHIS' drug price negotiation power, while various fields are proposing the introduction of a system that is first registered and evaluated later for access to treatments for severe rare and intractable diseases. Regarding referring to Korean drug prices such as China, the government also said it is actively responding by expanding RSA to prepare for "China risks" such as "Korea Passing."

The MOHW recently submitted the "2020 National Assembly Processing Results Report on the Requirements for Correcting and Processing the National Assembly" with such contents.

First of all, the National Assembly previously demanded the MOHW